ClinicaliQ Trial Snapshot
- Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer — Recruiting • Phase II • Oncology • NCT07808151.
- What is being tested: The combination of two immunotherapy agents—porustobart and pembrolizumab—administered before surgery (neoadjuvant approach) in patients with resectable, microsatellite stable/proficient mismatch repair (MSS/pMMR) colon cancer, which typically shows poor response to immunotherapy alone.
- Patient eligibility overview: Adults with resectable colon cancer that is confirmed as MSS or pMMR; the trial focuses on this specific molecular subtype which represents the majority of colorectal cancers and has historically limited benefit from single-agent immunotherapy.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this clinical trial is to learn if giving two medicines together, porustobart and pembrolizumab, before surgery can treat a common type of colon cancer called microsatellite stable (MSS) colon cancer in adults. This type of cancer can be removed with surgery and has not spread to other parts of the body. Both medicines work by helping the immune system fight cancer. The main questions this study wants to answer: How well do the medicines destroy the cancer before surgery? What side effects do participants have when taking…
Eligibility Snapshot
- : ≥18 years of age at consent Adenocarcinoma of the colon (rectosigmoid considered non-rectal); pMMR/MSS status Any T3 or T4, N any, M0; disease amenable to surgical resection ECOG Performance Status 0-1 Adequate tumor tissue sample with associated pathology report Adequate hematologic, hepatic, and renal function Reproductive status/contraception requirements per protocol
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.